NCT06466434Recruiting
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
To learn about the possible effects of a prebiotic food-enriched diet (PreFED) targeting the gut microbiome in participants with melanoma who are starting immune checkpoint blockade (ICB) therapy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 14 Jun 2024
- Start date
- 1 Sept 2024
- Primary completion date
- 30 Jun 2028
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Melanoma
- NCT number
- NCT06466434
What you commit to
- Study type: Interventional
- Planned participants: 75
- From 1 Sept 2024 to the primary completion date, 30 Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous ICB treatment in the metastatic setting
- Currently taking steroids \> Prednisone 10 mg/day or equivalent
- Current smoker or heavy drinker (defined as \>14 drinks per week) or current illicit drug use.
- Concurrent malignancy requiring systemic therapy other than hormonal therapy.
Other illness
- History of inflammatory bowel disease, total colectomy, or bariatric surgery.
- Self-reported major dietary restrictions, including but not limited to relevant food allergies, celiac disease, or diets such as vegan, ketogenic, extended fasting.
- Insulin-dependent diabetes or condition requiring bile acid sequestrants
Other
- Medical contraindications to the Intervention Diet as determined by the treating physician.
- Unable or unwilling to undergo study procedures.
- IV antibiotic use in the past month or oral antibiotic use in past 2 weeks.
- Regularly taking supplements containing prebiotics, fiber and/or probiotics, and unable/unwilling to discontinue for the purpose of the study.
- Currently pregnant, planning to become pregnant, or lactating.
- Cognitively impaired adults
Who the study is looking for
- Age ≥18 years old
- English-speaking
- Body mass index (BMI) 18.5-45 kg/m2
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Histologically confirmed stage III/IV, unresectable cutaneous, uveal, acral or mucosal melanoma. Asymptomatic brain metastases are allowed.
- Planned initiation of 1st line standard-of-care approved immune checkpoint blockade (anti-PD1 +/- anti-CTLA4 or anti-LAG3 inhibitors or talimogene laherparepvec T-VEC) in the metastatic setting. Prior targeted therapy or ICB in the adjuvant setting is allowed.
- Returning to MD Anderson for restaging and follow-up (ICB treatment may occur locally)
- Measurable disease per RECIST 1.1 or RANO criteria. Up to 10 patients without measurable can be enrolled.
- WOCP must have negative UPT within 1 week of beginning dietary intervention.
- Self-reported willingness to eat the provided foods (with some tailoring to their food preferences)
- Self-reported willingness to comply with scheduled visits, undergo venipuncture, provide stool samples.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.